A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease

J Pediatr. 2003 Sep;143(3):357-62. doi: 10.1067/S0022-3476(03)00330-5.

Abstract

Objective: To investigate whether a polymorphism in the CD14 gene is associated with Kawasaki disease (KD).

Study design: We extracted DNA from the whole blood of 69 control children and 67 patients with KD. We determined a polymorphism in the CD14 gene at position -159 upstream from the major transcription site (CD14/-159) by restriction fragment assay. We then investigated the association between CD14/-159 and the onset of KD and development of coronary artery lesion (CAL).

Results: The genomic and allelic frequencies of the polymorphism were not different between normal children and KD patients. The KD patients with TT genotypes at CD14/-159 had more CAL complications than those with CT and CC (OR, 4.05; 95% CI, 1.34-12.22). The frequencies of the T allele was significantly higher than that of the C allele in KD patients with CAL (OR, 2.20; 95% CI, 1.23-3.94). Their data were confirmed in the patients whether the patients were treated with intravenous gamma-globulin. KD patients with TT genotypes had significantly higher levels of C-reactive protein and vascular endothelial growth factor, which had previously been reported as risk factors for CAL, than those with CC genotypes.

Conclusion: These results indicate that the T allele and TT genotype at CD14/-159 are risk factors for CAL in KD, and that the development of CAL in KD may be related to the magnitude of CD14 toll-like receptor response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / blood
  • Child, Preschool
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / etiology*
  • Coronary Artery Disease / genetics*
  • Endothelial Growth Factors / blood
  • Female
  • Genotype
  • Hepatocyte Growth Factor / blood
  • Humans
  • Lipopolysaccharide Receptors / blood
  • Lipopolysaccharide Receptors / genetics*
  • Male
  • Mucocutaneous Lymph Node Syndrome / blood
  • Mucocutaneous Lymph Node Syndrome / complications*
  • Mucocutaneous Lymph Node Syndrome / genetics*
  • Polymorphism, Genetic / genetics*
  • Promoter Regions, Genetic / genetics*
  • Tumor Necrosis Factor-alpha / analysis
  • Vascular Endothelial Growth Factor A / blood

Substances

  • Antineoplastic Agents
  • Endothelial Growth Factors
  • Lipopolysaccharide Receptors
  • Tumor Necrosis Factor-alpha
  • Vascular Endothelial Growth Factor A
  • Hepatocyte Growth Factor